GenSight Biologics

105 articles about GenSight Biologics

• GenSight Biologics Announces Additional Promising Results Of Its Phase I/II Study With GS010 For The Treatment Of Leber’s Hereditary Optic Neuropathy (LHON)

  6/8/2016

• GenSight Biologics Closes $36 Million Series B Funding Round

  7/23/2015

• GenSight Biologics Appoints Thomas Gidoin As Chief Financial Officer & Michael Wyzga To Board Of Directors

  7/7/2015

• Eye Sees More Gene Therapy: GenSight Biologics Files For A $100 Million IPO

  7/7/2015

• GenSight Biologics, Pixium Vision And Fondation Voir Et Entendre Join Forces And Benefit From A Total € 18.5 Million Funding For SIGHT AGAIN As Part Of The Investment For The Future

  1/7/2015